Meperidine, Urine Screen with Reflex to Quantitation
Also known as: MEP RFX U
Use
This test is useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out meperidine exposure. If the specimen screens positive, it undergoes Confirmation/Quantitation by gas chromatography-mass spectrometry (GC-MS) to confirm results. This approach ensures high accuracy by confirming presumptive positive results, making it particularly useful in clinical and compliance settings where accurate detection of meperidine exposure is required.
Special Instructions
Random urine without any additives or preservatives should be collected. The sample must be transferred to an ARUP Standard Transport Tube. If the specimen screens positive by the initial immunoassay, it will be reflexed to quantitative testing using GC-MS. Additional charges apply for confirmation testing.
Limitations
Presumptive negative results for drugs and/or drug metabolites may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of the testing method. The screening test's ability to detect drugs or metabolites may vary within a drug class. This test is for medical purposes only and is not valid for forensic use.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 54247-2
- 3746-5
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4 mL
Minimum Volume
2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transfer with no additives or preservatives to an ARUP Standard Transport Tube.
Causes for Rejection
Specimens collected in tubes with additives or preservatives.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |